Despite many calls for case‐based operations management research, the successful publication rate of such articles in top‐tier journals has been less than stellar. A five step case‐based research and dissemination process is presented. Guidance is given to future researchers for each step in the process. In addition, areas of weakness are examined and discussed in detail. Future potential research questions in operations management considered to be appropriate for the case‐based method are highlighted.

Recently, there have been numerous calls for more empirical field‐based research to be conducted in operations management (OM). Knowledge of how operations systems work can be enhanced significantly through contact with the “real‐world” conditions that OM models seek to describe. Case study research is a primary means of exploring field conditions but is an unfamiliar methodology for many in OM. Moreover, the case study method is viewed with scepticism by those who consider it to be a weak form of research, one that lacks rigor and objectivity.Here, we offer an introduction to the case study method for OM researchers who may have little background in field based research. We provide an outline of the procedure and cite some excellent sources that cover case study design, data analysis and the philosophical rationale for the methodology. We also identify some recent examples of OM case studies that illustrate our points. We then contrast the various uses for case study research and their different design and theory requirements. An appendix provides a listing of case studies that have appeared in some OM journals in recent years, classifying the studies by their research purpose.However, regardless of their purposes, case study research need to be conducted in a manner that assures maximum measurement reliability and theory validity. We describe some of the steps that must be taken to ensure that a study is as rigorous as possible. We also argue that, properly conducted, a case study is a truly scientific research approach. We conclude by pointing out some areas of OM research where case studies might be particularly valuable.

This study tests a path analytic model of buyer-supplier relationships, linking the supplier's level of trust to three categories of inter-firm cooperative behaviors and these behaviors to the buyer's perception of the relationship's performance. Data was used from a survey of 164 dyads composed of a purchasing manager and a counterpart in a firm that they identified as their most cooperative suppliers. Higher levels of inter-organizational cooperative behaviors such as shared planning and flexibility in coordinating activities were found to be strongly linked to the supplier's trust in the buyer firm. However, not all of the types of cooperative behaviors, particularly joint responsibility for problem solving, had significant impacts on the buyer's perceptions of the relationship's performance.

Supplier alliances have been widely touted but there are probably a limited number of situations where they are applicable. This paper develops a model of important factors that define which suppliers offer the best choices for pursuing alliance‐like relationships. Some factors relate to the technology of the goods or services being sourced; others relate to the ability to develop mutual goodwill trust with the targeted supplier. The model was developed through a combination of extensive literature reviews and a series of interviews with managers in 15 manufacturing and service firms.

Pharmacologic expansion of endogenous β cells is a promising therapeutic strategy for diabetes. To elucidate the molecular pathways that control β-cell growth we screened ∼2400 bioactive compounds for rat β-cell replication-modulating activity. Numerous hit compounds impaired or promoted rat β-cell replication, including CC-401, an advanced clinical candidate previously characterized as a c-Jun N-terminal kinase inhibitor. Surprisingly, CC-401 induced rodent (in vitro and in vivo) and human (in vitro) β-cell replication via dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) 1A and 1B inhibition. In contrast to rat β cells, which were broadly growth responsive to compound treatment, human β-cell replication was only consistently induced by DYRK1A/B inhibitors. This effect was enhanced by simultaneous glycogen synthase kinase-3β (GSK-3β) or activin A receptor type II-like kinase/transforming growth factor-β (ALK5/TGF-β) inhibition. Prior work emphasized DYRK1A/B inhibition-dependent activation of nuclear factor of activated T cells (NFAT) as the primary mechanism of human β-cell-replication induction. However, inhibition of NFAT activity had limited effect on CC-401-induced β-cell replication. Consequently, we investigated additional effects of CC-401-dependent DYRK1A/B inhibition. Indeed, CC-401 inhibited DYRK1A-dependent phosphorylation/stabilization of the β-cell-replication inhibitor p27Kip1. Additionally, CC-401 increased expression of numerous replication-promoting genes normally suppressed by the dimerization partner, RB-like, E2F and multivulval class B (DREAM) complex, which depends upon DYRK1A/B activity for integrity, including MYBL2 and FOXM1. In summary, we present a compendium of compounds as a valuable resource for manipulating the signaling pathways that control β-cell replication and leverage a DYRK1A/B inhibitor (CC-401) to expand our understanding of the molecular pathways that control β-cell growth.